Table 1.
Characteristics of the samples used for the Linkage-Disequilibrium SCore regression (LDSC) and GeNetic cOVariance Analyzer (GNOVA) analyses.
Trait/disorder | Author | Year | PMID | Consortium | Ancestry | N | Cases | Controls | Neff |
---|---|---|---|---|---|---|---|---|---|
2hGlu | Saxena et al. | 2010 | 20081857 | MAGIC | European | 15,234 | |||
BMI | Pulit et al. | 2019 | 30239722 | GIANT | European | 697,734 | |||
FPG | Lagou et al. | 2021 | 33402679 | MAGIC | European | 140,595 | |||
FPI | Lagou et al. | 2021 | 33402679 | MAGIC | European | 98,210 | |||
HbA1c | Wheeler et al. | 2017 | 28898252 | MAGIC | European | 123,665 | |||
HOMA-IR | Dupuis et al. | 2010 | 20081858 | MAGIC | European | 37,037 | |||
MetS | Lind | 2019 | 31589552 | European | 291,107 | 59,677 | 231,430 | 189,772.64 | |
Obesity | Watanabe et al. | 2019 | 31427789 | European | 244,890 | 9805 | 235,085 | 37,649.69 | |
T2DM | Mahajan et al. | 2018 | 30297969 | DIAGRAM | European | 898,130 | 74,124 | 824,006 | 272,025.75 |
ADHD | Demontis et al. | 2019 | 30478444 | PGC | European | 53,293 | 19,099 | 34,194 | 49,017.41 |
AD | Wightman et al. | 2021 | 34493870 | PGC | European | 762,917 | 86,531 | 676,386 | 306,866.18 |
AN | Watson et al. | 2019 | 31308545 | PGC | European | 72,517 | 16,992 | 55,525 | 52,041.91 |
ASD | Grove et al. | 2019 | 30804558 | PGC | European | 46,350 | 18,381 | 27,969 | 44,366.62 |
BD | Mullins et al. | 2021 | 34002096 | PGC | European | 413,466 | 41,917 | 371,549 | 150,669.89 |
OCD | OCGAS/IOCDF-GC | 2018 | 28761083 | OCGAS/IOCDF-GC | European | 9725 | 2688 | 7037 | 7780.14 |
MDD | Wray et al./Howard et al. | 2019 | 29700475/ 29662059 | PGC | European | 500,199 | 170,756 | 329,443 | 449,855.91 |
SCZ | Pardinas et al. | 2018 | 29483656 | PGC + CLOZUK | European | 105,318 | 40,675 | 64,643 | 99,863.42 |
TS | Yu et al. | 2019 | 30818990 | PGC | European | 14,307 | 4819 | 9488 | 12,783.30 |
2hGlu glucose levels 2 h after an oral glucose challenge, BMI body mass index, FPG fasting plasma glucose, FPI fasting plasma insulin, HbA1c glycated haemoglobin, HOMA-IR homeostatic model assessment for insulin resistance, MetS metabolic syndrome, T2DM type 2 diabetes mellitus, ADHD attention-deficit/hyperactivity disorder, AD Alzheimer’s disease, AN anorexia nervosa, ASD autism spectrum disorder, BD bipolar disorder, MDD major depressive disorder, OCD obsessive-compulsive disorder, SCZ schizophrenia, TS Tourette’s syndrome, N total sample size, Neff effective sample size [Neff = 4/(1/Cases + 1/Controls)].